Solopharm has successfully passed a pharmaceutical inspection and obtained a certificate of compliance with Good Manufacturing Practice (GMP) requirements in the Republic of Uzbekistan.
The certificate was issued based on a completed audit conducted in accordance with the established regulations for inspection procedures for compliance with Good Manufacturing Practice (GMP). Following the inspection, the company's manufacturing processes were recognized as compliant with national quality and safety standards.
Obtaining the GMP certificate confirms the high level of Solopharm's production organization and strict quality control at all stages — from development and product release to storage and distribution — and aligns with the company's strategy to expand its international presence.
As part of the development of its export activities, Solopharm is also in the active preparation stage for a GMP audit by ANVISA, Brazil's national regulatory authority. The audit is scheduled for 2026, and the company intends to complete the Brazilian GMP certification in 2027.
Solopharm is consistently developing its export markets and pays special attention to compliance with global regulatory requirements. The GMP certification in Uzbekistan creates additional opportunities for strengthening the company's position in Central Asian markets and expanding patient access to high-quality and effective pharmaceutical products.
